Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.

NCT04045847 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT04045847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04045847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.
Lead sponsor
Xijing Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 30, 2019
Completion date
May 30, 2022
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd147 positive, recurrent glioblastoma